ClinicalTrials.gg
RecruitingNCT07713680Updated Oct 16, 2026

β2M Post-HD Rebound Prediction

An observational study in Renal Disease, End Stage, sponsored by East and North Hertfordshire NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by East and North Hertfordshire NHS Trust · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Kidney Failure, Chronic with a site in United Kingdom — 15 open to participants now, 23 under way, 5 of them phase 3. Kidney Failure, Chronic · United Kingdom.

Planned enrollment
17th of 26
30 · median 94
Started
2026
the only one that year
Observational
26 of 103
7 open now
Primary completion
2026-11
later than 6 of 22 live
Registered
103rd of 103
by date
Lead sponsor
3 of 103
East and North Hertfordshire NHS Trust

Among the 103 studies in Kidney Failure, Chronic with a site in United Kingdom, this one is the 17th largest by planned enrollment of the 26 observational ones that give a count, is the only one that started in 2026, is one of 26 observational ones, reaches primary completion later than 6 of the 22 other live ones, and was the 103rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

15 of the 103 studies in Kidney Failure, Chronic with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Kidney Failure, Chronic with a site in United Kingdom, or all of them as a file.
02

Study summary

β2-Microglobulin is small 11.8 kDa protein presents on the surface of all nucleated cell in the human body, it forms part of the non-variable chain of Major Histocompatibility Complex class I. β2-Microglobulin production is constant and it is continuously released into the bloodstream. Its production increases during active infections, inflammation or blood cancers. The Kidneys are the main route of its elimination. It accumulates in patients with kidney disease and levels can rise significantly in patients with end-stage renal failure. Studies have shown that its accumulation in dialysis patients contributes to dialysis-related amyloidosis.

Haemodialysis is a significant contributor to removal of β2-microglobulin in those on dialysis. It removes β2-microglobulin from the blood rather than directly from tissues. Blood levels fall during dialysis. However, after haemodialysis, β2-microglobulin gradually moves from tissues into the bloodstream until equilibrium is reached (post-dialysis rebound). Our own published data and unpublished data suggest this rebound occurs by two hours post-dialysis approximately but is significant in magnitude. β2-Microglobulin is increasingly recognized as an important marker of middle-molecule solute clearance.

The investigators plan to recruit thirty haemodialysis patients. During two dialysis sessions blood samples will be taken to measure β2-microglobulin. During the first session, samples will be taken pre-dialysis and at intervals during the session. Post-dialysis samples will be taken at 1 and 2 hour time points. The investigators will perform a physical examination, fluid/nutrition assessment. Dialysis prescription and routine monthly blood and urine results will also be recorded, and patients will be asked to complete questionnaires about dialysis symptoms, fatigue and post-dialysis recovery time. At the start of the next dialysis, one final β2-microglobulin sample will be taken.

β2-microglobulin removal may be a useful marker of dialysis quality. The investigators aim to develop a predictive model to estimate the equilibrated β2-microglobulin to allow its dialysis clearance to be accurately assessed.

03

Conditions studied

  • Renal Disease, End Stage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants are those with ESRD undergoing Haemodialysis for at least 3 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or above.
  • Ability to give .
  • End Stage Renal Disease established on maintenance haemodialysis for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Inability to give .
  • Acute infection in last 2 weeks.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • End Stage Renal Disease on haemodialysis

    Adult, End Stage Renal Disease established on maintenance haemodialysis for at least 3 months

    Diagnostic Test: β2-microglobulin blood concentration in mg/L

Interventions

  • Diagnostic testβ2-microglobulin blood concentration in mg/L

    Blood samples for β2-microglobulin measurement will be collected by study investigator across two haemodialysis sessions. During the first study visit (HD1), blood samples will be obtained pre-dialysis (0%), at 20%, 40%, 60%, and 80% of the prescribed dialysis duration, at the end of dialysis (100%), and at 1 hour and 2 hours following completion of dialysis. During the second study visit (HD2), a single pre-dialysis β2-microglobulin sample will be collected at the start of the participant's next routine haemodialysis session, which is second and last study visit. All study samples will be used to measure β2-Microglobulin concentration in mg/L

06

What researchers measure

Primary outcomes

  1. Post-dialysis β2-microglobulin blood concentration (mg/L) at 1 and 2 hours after completion of haemodialysis

    β2-microglobulin blood samples will be collected at time points including pre-dialysis (0%), at 20%, 40%, 60%, 80%, and 100% of the dialysis session, as well as at 1 hour and 2 hours post-dialysis. An additional pre-dialysis sample will be obtained before the next routine haemodialysis session (approximately 48 hours later). The primary outcome measure will be the β2-microglobulin concentration (mg/L) at 1 and 2 hours post-dialysis, which will serve as the dependent variable in regression-based and software-assisted modelling. These models will be used to develop an algorithm capable of accurately predicting the equilibrated post-dialysis β2-microglobulin concentration from measurements obtained during the dialysis session.

    Time frame: The study is very short study (Over 2 days)

Secondary outcomes

  1. The investigator will record small panel of solute clearance markers such as blood urea measured in mmol/L and creatinine umol/L

    This is recorded from the standard of care blood tests assessing monthly dialysis adequacy. Derived from routine monthly dialysis adequacy testing done at same time period of the study sample collection.

    Time frame: The study is very short study (Over 2 days)

  2. The Investigator will assess Patient-Reported Outcome Measures (PROMs) related to dialysis quality and dialysis-associated symptom burden, using validated questionnaires

    The following validated Questionnaires will be used to assess Patient Reported Outcome Measure (PROM): SONG-HD Fatigue, Recovery time and IPOS Renal questionnaires . The questionnaire burden was discussed at the Patients and Public Involvement Group meeting within the trust and considered in study design. The questionnaires were considered relevant and the burden on patients was judged to be acceptable and not a major barrier to participation. To minimise the participants being overwhelmed with questionnaires, The Investigator will offer them flexibility of completing the questionnaires during and or after first study visit (either on dialysis or at home). The Participants may also receive support from family, friend and or medical staff team to help filling these questionnaires as needed. It is anticipated that each questionnaire will take approximately 5 minutes to complete. The investigator expect most patients will complete this during their dialysis treatment

    Time frame: The study is very short study (Over 2 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Aug 2026 → Nov 2026 and completion Aug 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Jul 20, 2026
StartActual
Feb 24, 2026
Primary completionEst.
Nov 2026was Aug 2026
CompletionEst.
Nov 2026was Aug 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Nov 2026
Oct 16, 2026
Study completion
Aug 2026→Nov 2026
Oct 16, 2026
Eligibility
Revised
Oct 16, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedWeThe investigator will record small panel of solute clearance markers such as blood urea measured in mmol/L and creatinine umol/LTime frame: The study is very short study (Over 2 days)
  • EditedWeThe Investigator will assess Patient-Reported Outcome Measures (PROMs) related to dialysis quality and dialysis-associated symptom burden, using validated questionnairesTime frame: The study is very short study (Over 2 days)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Aug 2026→Nov 2026
    Study completion Aug 2026→Nov 2026
    Eligibility Revised
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedWeThe investigator will record small panel of solute clearance markers such as blood urea measured in mmol/L and creatinine umol/LTime frame: The study is very short study (Over 2 days)
    • EditedWeThe Investigator will assess Patient-Reported Outcome Measures (PROMs) related to dialysis quality and dialysis-associated symptom burden, using validated questionnairesTime frame: The study is very short study (Over 2 days)
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07713680
Lead sponsor
East and North Hertfordshire NHS Trust
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Feb 24, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Shaza Adam, Clinical research Fellow
Contact
Shaza.adam@nhs.net
00447365073834 ext. 01438287884340
Enric Vilar, Consultant Nephrologist and Se
Contact
enric.vilar@nhs.net
Shaza Adam
principal investigator · Lister Hospital, East and North Hertfordshire Teaching NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion